Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05964907

Optimizing Phototesting and Investigating Photobiology of Visible Light

Specific Aim 1: To determine the impact of spectral composition of the VL+UVA1 source on the associated biologic effects.

Specific Aim 2: To investigate differential responses of subjects with different skin phototypes to VL+UVA1, including immediate and delayed erythema and pigmentation, and photodamage.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Healthy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Henry Ford Medical Center

Detroit, Michigan, 48202, United States

About this study

The design of the study consists of a total of 4 visits within a two week period. The first visit consists of VL+UVA1 irradiation with different light source on the opposite site of patients' back. A combination of non-invasive measurements (e.g., photography, redness and color changes of the skin using colorimetry and diffuse reflectance spectrometry) will be conducted throughout the 4 visits. Biopsies will be taken at various time points.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy individuals age 18 and older
  • Fitzpatrick skin phototype (SPT) I-VI, 7 with SPT I-III and 7 with SPT IV-VI, with normal healthy skin
  • Able to understand the requirements of the study and its associated risks
  • Able to complete and sign a consent form
  • Willing and able to refrain from any medications or herbal supplements during the duration of the study, unless permitted by the investigator
  • Agrees to refrain from using any new topical skin care products, laundry detergents, or fragrances while participating in the study
  • Has not had excessive sun exposure for 7 days prior to enrollment in the study

Exclusion criteria

  • Recent history of vitiligo, melasma, and other disorders of pigmentation with the exception of post-inflammatory hyperpigmentation
  • History of relevant skin conditions such as atopic dermatitis, eczema, or sunburn on any part of the body
  • History of photodermatoses or photosensitivity disorders
  • History of melanoma or non-melanoma skin cancers
  • Use of tanning parlors or exposure of the irradiated sites to sun light during the duration of the study
  • Use of topical or systemic treatment that is likely to interfere with assessment, study results, or pose safety concerns
  • Subjects with a tendency to bleed excessively
  • Known allergies to anesthetics (lidocaine) or anaphylaxis treatment (epinephrine)
  • History of hypertrophic scarring or keloid formation
  • Use of any photosensitizing medication within the visible light range or additional medication at the discretion of the investigator [examples include - but not limited to - thiazide diuretics, regular use of NSAIDs, hydroxychloroquine, or voriconazole
  • A woman who is lactating, pregnant, or planning to become pregnant

Treatment and study plan

Light Source B: Visible Light solar simulator (VL + UVA1)

Device

Patients will be radiated with light source B (Visible light solar simulator)

Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)

Device

Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)

Primary outcomes

  1. Erythema assessment for all 14 participants.

    Time frame: Visit 1 (Day 0)

    Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Erythema (Redness) 0 Clear of erythema

    • Almost clear of erythema
    • Mild, but noticeable erythema
    • Moderate erythema (pink), no sharp borders
    • Severe erythema (dark pink), sharp borders
    • Very severe erythema (very dark pink to almost red)

  2. Erythema assessment for all participants

    Time frame: Visit 2 (Day 1)

    Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Erythema (Redness) 0 Clear of erythema

    • Almost clear of erythema
    • Mild, but noticeable erythema
    • Moderate erythema (pink), no sharp borders
    • Severe erythema (dark pink), sharp borders
    • Very severe erythema (very dark pink to almost red)

  3. Erythema assessment

    Time frame: Visit 3 (Day 7)

    Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Erythema (Redness) 0 Clear of erythema

    • Almost clear of erythema
    • Mild, but noticeable erythema
    • Moderate erythema (pink), no sharp borders
    • Severe erythema (dark pink), sharp borders
    • Very severe erythema (very dark pink to almost red)

  4. Erythema assessment for 14 participants

    Time frame: Visit 4 (Day 14)

    Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Erythema (Redness) 0 Clear of erythema

    • Almost clear of erythema
    • Mild, but noticeable erythema
    • Moderate erythema (pink), no sharp borders
    • Severe erythema (dark pink), sharp borders
    • Very severe erythema (very dark pink to almost red)

  5. Erythema assessment for all 14 participants

    Time frame: Visit 1 (Day 0)

    Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L* and a* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L* and b* by using ITA = [arctan (L* - 50)/b*] X 180/Π)].

    Colorimetry: Decrease in L* and ITA indicates greater pigmentation. Increase in a* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

  6. Erythema assessment for all 14 participants

    Time frame: Visit 2 (Day 1)

    Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L* and a* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L* and b* by using ITA = [arctan (L* - 50)/b*] X 180/Π)].

    Colorimetry: Decrease in L* and ITA indicates greater pigmentation. Increase in a* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

  7. Erythema assessment for all 14 participants

    Time frame: Visit 3 (Day 7)

    Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L* and a* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L* and b* by using ITA = [arctan (L* - 50)/b*] X 180/Π)].

    Colorimetry: Decrease in L* and ITA indicates greater pigmentation. Increase in a* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

  8. Erythema assessment for all 14 participants

    Time frame: Visit 4 (Day 14)

    Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L* and a* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L* and b* by using ITA = [arctan (L* - 50)/b*] X 180/Π)].

    Colorimetry: Decrease in L* and ITA indicates greater pigmentation. Increase in a* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

  9. Pigmentation assessment for all 14 participants.

    Time frame: Visit 1 (day 0)

    Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Pigmentation (Tanning) 0 Clear of hyperpigmentation

    • Almost clear of hyperpigmentation
    • Mild, but noticeable hyperpigmentation
    • Moderate hyperpigmentation (medium brown)
    • Severe hyperpigmentation (dark brown)
    • Very severe hyperpigmentation (very dark brown to almost black)

  10. Pigmentation assessment for all 14

    Time frame: Visit 2 (Day 1)

    Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Pigmentation (Tanning) 0 Clear of hyperpigmentation

    • Almost clear of hyperpigmentation
    • Mild, but noticeable hyperpigmentation
    • Moderate hyperpigmentation (medium brown)
    • Severe hyperpigmentation (dark brown)
    • Very severe hyperpigmentation (very dark brown to almost black)

  11. Pigmentation assessment for 14 participants

    Time frame: Visit 3 (Day 7)

    Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Pigmentation (Tanning) 0 Clear of hyperpigmentation

    • Almost clear of hyperpigmentation
    • Mild, but noticeable hyperpigmentation
    • Moderate hyperpigmentation (medium brown)
    • Severe hyperpigmentation (dark brown)
    • Very severe hyperpigmentation (very dark brown to almost black)

  12. Pigmentation assessment for all 14

    Time frame: Visit 4 (Day 14)

    Measured clinically with Investigator Global Assessment (IGA) scale IGA Description of Pigmentation (Tanning) 0 Clear of hyperpigmentation

    • Almost clear of hyperpigmentation
    • Mild, but noticeable hyperpigmentation
    • Moderate hyperpigmentation (medium brown)
    • Severe hyperpigmentation (dark brown)
    • Very severe hyperpigmentation (very dark brown to almost black)

  13. Pigmentation assessment for all 14 participants..

    Time frame: Visit 1 (day 0)

    Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L* and a* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L* and b* by using ITA = [arctan (L* - 50)/b*] X 180/Π)].

    Colorimetry: Decrease in L* and ITA indicates greater pigmentation. Increase in a* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

  14. Pigmentation assessment for all 14 participants

    Time frame: Visit 2 (Day 1)

    Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L* and a* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L* and b* by using ITA = [arctan (L* - 50)/b*] X 180/Π)].

    Colorimetry: Decrease in L* and ITA indicates greater pigmentation. Increase in a* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

  15. Pigmentation assessment for all 14 participants

    Time frame: Visit 3 (Day 7)

    Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L* and a* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L* and b* by using ITA = [arctan (L* - 50)/b*] X 180/Π)].

    Colorimetry: Decrease in L* and ITA indicates greater pigmentation. Increase in a* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

  16. Pigmentation assessment for all 14 participants

    Time frame: Visit 4 (Day 14)

    Both colorimetry and DRS non-invasively provide quantitative objective information regarding changes in skin color by quantifying skin hyperpigmentation and erythema as L* and a* by colorimeter, and as melanin, oxy-hemoglobin concentration by DRS respectively. ITA can be derived from L* and b* by using ITA = [arctan (L* - 50)/b*] X 180/Π)].

    Colorimetry: Decrease in L* and ITA indicates greater pigmentation. Increase in a* indicates increase in Erythema. All these parameters are relative with arbitrary units DRS: Increase in Melanin content will indicate increase in pigmentation and increase in oxy-hemoglobin will indicate increase in erythema. All these parameters are relative with arbitrary units

Secondary outcomes

  1. Immunohistochemical changes in pigmentation, inflammation, and profileration, for all 14 participants

    Time frame: Visit 1 (Day 0)

    Histology assess parameter including pigmentation, inflammation and proliferation.

  2. Immunohistochemical changes in pigmentation, inflammation, and profileration, for all 14 participants

    Time frame: Visit 2 (Day 1)

    Histology assess parameter including pigmentation, inflammation and proliferation.

  3. Immunohistochemical changes in pigmentation, inflammation, and profileration, for all 14 participants

    Time frame: Visit 3 (Day 7)

    Histology assess parameter including pigmentation, inflammation and proliferation.

  4. RNA sequencing for 8 participants

    Time frame: Visit 2 (Day 1)

    Molecular changes- sample collection for RNA sequencing

Sponsors and collaborators

Lead sponsor

Henry Ford Health System

Other

Registry information

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Jul 28, 2023
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.